Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Related Keywords
Omar Boraie , Shridar Ganesan , Rwjbarnabas Health , Rutgers Cancer Institute Of New Jersey , Molecular Oncology , Translational Science , Omar Boraie Chair , Genomic Science , Rutgers Cancer Institute , New Jersey , Ctdna , Yard , Cancer Care , Rutgers ,
vimarsana.com © 2020. All Rights Reserved.